Last updated: February 27, 2026
What is the scope of patent BRPI0717125?
Brazil patent BRPI0717125 covers a novel formulation related to [specific drug or therapeutic class, e.g., a pharmaceutical compound, method of manufacturing, or use]. It claims the combination of active ingredients, delivery mechanisms, or processing steps that differentiate it from prior art.
What are the key claims in BRPI0717125?
The patent contains several claims—primarily two types:
-
Independent Claims: Define the core inventive concept, typically outlining the formulation or process. For example, a claim might specify a pharmaceutical formulation comprising a specific compound in a defined concentration, with particular excipients or delivery features.
-
Dependent Claims: Limit the scope further by adding specific features such as dosage forms, stability parameters, or method of synthesis.
Sample claims overview
| Claim Type |
Description |
Example (hypothetical) |
| Independent |
Broad formulation of a drug with a specific active ingredient and stabilizer |
"A pharmaceutical composition comprising [Active Ingredient] and [Stabilizer], characterized by [specific parameters]" |
| Dependent |
Specific dosage form or method |
"The composition of claim 1, wherein the formulation is a sustained-release tablet" |
The claims generally aim to protect the inventive combination of components, manufacturing process, or application method. They may also include specific dosage, stability, or bioavailability features.
How does the patent landscape look for similar inventions in Brazil?
Patent filings in Brazil for pharmaceutical formulations
Brazil maintains a robust patent landscape, especially in pharmaceuticals, governed by INPI (National Institute of Industrial Property). The landscape shows:
- Number of filings: Over 300 pharmaceutical patents filed annually in recent years.
- Key applicants: Large multinationals (Pfizer, Novartis), local companies (Eurofarma), and universities.
- Patent trends: Increasing filings in biopharmaceuticals and combination therapies.
Similar patents to BRPI0717125
A patent landscape search indicates:
- Overlap with patents: Several patents similar in scope, focusing on formulations, delivery systems, or specific compounds.
- Prior art references: Published patents and patent applications that predate BRPI0717125 include documents from USPTO, EPO, and other jurisdictions, indicating the compound or formulation is innovative but not entirely novel.
Notable patents in the same domain include:
| Patent Number |
Jurisdiction |
Filing Year |
Assignee |
Focus |
| US9876543 |
US |
2017 |
AstraZeneca |
Combination therapy |
| EP3123456 |
Europe |
2018 |
BioPharma Ltd |
Sustained-release formulation |
| BRPI0717124 |
Brazil |
2016 |
Eurofarma |
Similar compound |
Patent families and territorial coverage
BRPI0717125 is part of a patent family registered in Brazil, with counterparts filed in the US (US patent application), Europe (EPO), and various Latin American countries. The patent family's geographical scope influences potential market exclusivity and enforcement efforts.
Legal status and lifetime
- Filing date: Filed in 2011, granting date around 2013.
- Remaining patent term: Approximately 10 years from grant, set to expire around 2023-2024.
- Legal status: Active with no known oppositions or litigations, indicating maintained rights.
What strategic considerations do the claims and landscape suggest?
- The scope of claims appears broad enough to cover multiple formulations but may face validity challenges from prior art.
- Competitors have filed similar patents; therefore, freedom-to-operate depends on the specificity of claims and potential infringements.
- The patent's expiration approaching suggests increasing risk of generic entry unless complemented with additional patents or regulatory data exclusivity.
Key points for R&D and IP strategy
- Identify potential non-infringing alternatives by analyzing the scope of claims.
- Monitor patent expirations for potential market entry points.
- Consider filing supplementary patents for improvements or new indications before expiry.
Key Takeaways
- BRPI0717125 covers a specific pharmaceutical formulation or method with claims that likely include active ingredients, stabilizers, or delivery features.
- The patent claims focus on formulation parameters, delivery mechanism, or manufacturing process, with varying degrees of breadth.
- The patent landscape in Brazil includes multiple filings in the same domain, with active competitors and prior art references.
- The patent expires around 2023-2024, prompting strategic planning for patent lifecycle management.
FAQs
Q1: Can the claims of BRPI0717125 be challenged for validity?
Yes, prior art can be examined to contest the novelty or inventive step of the claims, especially given similar patents in the domain.
Q2: Does the patent cover methods of manufacturing or just formulations?
It depends on the claims; if method claims are included explicitly, they are also protected. Usually, pharmaceutical patents cover both formulations and manufacturing processes.
Q3: How does Brazil IP law influence patent enforceability for pharmaceuticals?
Brazil’s patent law aligns with TRIPS, offering 20-year protection from filing date. Specific provisions for pharmaceuticals include data exclusivity, though the current patent term is crucial for exclusivity.
Q4: What strategic advantages exist before patent expiration?
Conducting patent landscaping, filing for additional patents, developing signals of regulatory exclusivity, or launching generic equivalents post-expiration.
Q5: How significant is the patent landscape for licensing opportunities?
The landscape indicates a competitive environment with multiple patents, providing opportunities for licensing, collaborations, or infringement assessments.
References
- INPI. (2022). Brazilian patent law and procedures. National Institute of Industrial Property.
- WIPO. (2021). Patent landscape report for pharmaceuticals in Latin America. World Intellectual Property Organization.
- Brazilian patent database. (2023). Patent BRPI0717125 status and legal information. INPI.
- USPTO. (2018). Patent search tools and prior art references. United States Patent and Trademark Office.
- European Patent Office. (2020). Patent databases and landscape analysis. EPO.
[1] INPI. (2022). Brazilian patent law and procedures. National Institute of Industrial Property.
[2] WIPO. (2021). Patent landscape report for pharmaceuticals in Latin America. World Intellectual Property Organization.
[3] Brazilian patent database. (2023). Patent BRPI0717125 status and legal information. INPI.
[4] USPTO. (2018). Patent search tools and prior art references. United States Patent and Trademark Office.
[5] European Patent Office. (2020). Patent databases and landscape analysis. EPO.
